Download Slide ()

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Pharmacogenomics wikipedia , lookup

Discovery and development of beta-blockers wikipedia , lookup

Drug design wikipedia , lookup

CCR5 receptor antagonist wikipedia , lookup

Pharmacokinetics wikipedia , lookup

NMDA receptor wikipedia , lookup

5-HT3 antagonist wikipedia , lookup

Discovery and development of angiotensin receptor blockers wikipedia , lookup

Discovery and development of antiandrogens wikipedia , lookup

Toxicodynamics wikipedia , lookup

5-HT2C receptor agonist wikipedia , lookup

Psychopharmacology wikipedia , lookup

Bilastine wikipedia , lookup

Nicotinic agonist wikipedia , lookup

NK1 receptor antagonist wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Neuropharmacology wikipedia , lookup

Cannabinoid receptor antagonist wikipedia , lookup

Transcript
Logarithmic transformation of the dose axis and experimental demonstration of spare receptors, using different concentrations of an irreversible
antagonist. Curve A shows agonist response in the absence of antagonist. After treatment with a low concentration of antagonist (curve B), the curve is
shifted to the right. Maximal responsiveness is preserved, however, because the remaining available receptors are still in excess of the number required.
In curve C, produced after treatment with a larger concentration of antagonist, the available receptors are no longer “spare”; instead, they are just sufficient
to mediate an undiminished maximal response. Still higher concentrations of antagonist (curves D and E) reduce the number of available receptors to the
point that maximal response is diminished. The apparent EC50 of the agonist in curves D and E may approximate the Kd that characterizes the binding
Source: Drug Receptors & Pharmacodynamics, Basic & Clinical Pharmacology, 13e
affinity of the agonist for the receptor.
Citation: Katzung BG, Trevor AJ. Basic & Clinical Pharmacology, 13e; 2015 Available at: http://mhmedical.com/ Accessed: June 11, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved